Akero Therapeutics Inc.

AKRO | NASDAQ

Price Alert Chart Builder DCF Calculator

$54.65

$0 (0.00%)

At close: Dec 9, 2025, 4:00 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.00%

(1D)

Rating

Updated: Sep 21, 2026

7.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $4.5B

1D Range

54.52 54.65

52W Range

21.34 58.40

Valuation (TTM)

PE -14.38

PB 4.70

EV/EBITDA -13.48

Valuation (NTM)

Forward PE N/A

Forward PEG -4.17

Price Target $48.40

Cash Flow

FCF Yield -5.6%

SBC Adj. FCF Yield -6.4%

SBC Impact -12.8%

Margins

Gross Margin 0.0%

Operating Margin -8037075.0%

FCF Margin -6335600.0%

Growth (CAGR)

Revenue 3Y | 5Y 2.1% | 50.7%

Dil EPS 3Y | 5Y -21.0% | -7.6%

FCF 3Y | 5Y -43.2% | -33.1%

Returns

ROA -22.2%

ROE -21.8%

ROIC -26.3%

Financial Health

Net Cash

$736.95M

Current Ratio 15.83

Interest Coverage -73.72

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The ...

Sector Healthcare

Industry Biotechnology

Employees 69

IPO Date Jun 19, 2019

Website www.akerotx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$54

Downside

-1.19%

Buy (0)

Hold (4)

Sell (0)

Analyst Details ➞